X0306 4 2019-07-02 0 0001771917 Karuna Therapeutics, Inc. KRTX 0001219042 NELSEN ROBERT 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 1 0 1 0 Common Stock 2019-07-02 4 C 0 723644 A 723.644 I See Footnote Common Stock 2019-07-02 4 C 0 723643 A 723.643 I See Footnote Common Stock 2019-07-02 4 C 0 857793 A 1581437 I See Footnote Common Stock 2019-07-02 4 C 0 857792 A 1581435 I See Footnote Common Stock 2019-07-02 4 P 0 100000 16.00 A 1681437 I See Footnote Common Stock 2019-07-02 4 P 0 100000 16.00 A 1681435 I See Footnote Series A Preferred Stock 2019-07-02 4 C 0 557207 0.00 D Common Stock 723644 0 I See Footnote Series A Preferred Stock 2019-07-02 4 C 0 557206 0.00 D Common Stock 723643 0 I See Footnote Series A Preferred Stock 2019-07-02 4 C 0 660502 0.00 D Common Stock 857793 0 I See Footnote Series A Preferred Stock 2019-07-02 4 C 0 660501 0.00 D Common Stock 857792 0 I See Footnote The Series A Preferred Stock is convertible on a 1.2987-for-one basis into the number of shares of Common Stock shown in Column 3. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Preferred Stock has no expiration date. These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, L.P. , the sole general partner of ARCH IX, and shares voting and investment control with respect to these shares. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. The Series B Preferred Stock is convertible on a 1.2987-for-one basis into the number of shares of Common Stock shown in Column 3. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Preferred Stock has no expiration date. These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX Overage, L.P., the sole general partner of ARCH Overage, and shares voting and investment control with respect to these shares. The Reporting Person may be deemed to beneficially own the shares held by ARCH Overage. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. /s/ Troy Ignelzi, Attorney-in-Fact 2019-07-02